Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: SPL84
OTHER: Placebo

Sponsor

SpliSense Ltd.